STADA and ADCAN Pharma expand consumer healthcare options in UAE
European pharmaceutical player STADA and Abu Dhabi-based ADCAN Pharma announced a strategic agreement aimed at expanding patient access to high-quality medicines in the United Arab Emirates.
The collaboration combines ADCAN’s extensive product development and testing capabilities and local security of supply with STADA’s regional market expertise and strong promotional capabilities across pharmacies, clinics, polyclinics and hospitals in the Middle East and North Africa (MENA) region. With an annual production capacity of 500 million tablets and 80 million capsules, ADCAN Pharma meets all international requirements for pharmaceutical manufacturing.
In an initial phase of the collaboration, effective immediately, STADA will, on an exclusive basis, market and commercialize in the UAE a portfolio of 15 high-quality consumer healthcare products produced and supplied by ADCAN. These included registered skincare and first-aid products such as Dr Wound Gel and Silvano Spray, as well as several products currently under regulatory review that span therapeutic categories including allergy, pain-relief, sexual health, vitamins, minerals and supplements. Furthermore, two injectable analgesic formulations that are currently pending regulatory approval in the UAE are included in the agreement.
“We are excited about using STADA’s local marketing and sales strength to bring ADCAN Pharma’s portfolio to more people in the UAE,” explained Stéphane Jacqmin, STADA’s Head of Emerging Markets. “We have been hugely impressed by the state-of-the-art facility in Abu Dhabi, as well as by ADCAN’s capabilities in product development and stability testing and look forward to exploring opportunities to expand our partnership.”
Taha Khalidi, ADCAN’s COO/Acting CEO, commented: “Capitalizing on STADA’s strong market presence to bring our high-quality, locally-manufactured products will support our aspiration of becoming a pharma industry leader in the MENA region. Through our modern manufacturing site and proximity to market, we can make a meaningful contribution to security of medicines supply in the region.”
Last Updated on 6 months by News Desk 2
